Executive Team

Onno van de Stolpe - Chief Executive Officer

Onno van de Stolpe founded our company in 1999 and has served as our Chief Executive Officer and a member of our board of directors from 1999 to the present. From 1998 to 1999, he was the Managing Director of Genomics at IntroGene B.V. (later Crucell N.V., which was acquired by Johnson & Johnson Services, Inc. in 2011). Prior to joining IntroGene in 1998, he was Managing Director of Molecular Probes Europe B.V. He established this European headquarters after joining Molecular Probes, Inc. in the United States. Previously, he worked for The Netherlands Foreign Investment Agency in California, where he was responsible for recruiting biotechnology and medical device companies to locate in The Netherlands. Mr. Van de Stolpe started his career as Manager of Business Development at MOGEN International N.V. in Leiden. He received an MSc degree from Wageningen University. Mr. Van de Stolpe currently also serves as a member of the supervisory board of the Stichting Institute for Human Organ and Disease Model Technologies and has previously served as a member of the board of directors of DCPrime B.V.

Piet Wigerinck, PhD - Chief Scientific Officer

Dr. Piet Wigerinck joined Galapagos in April 2008 from Tibotec (a subsidiary of Johnson & Johnson) where he was VP Drug Discovery, Early Development and CM&C, and a member of the Management Board. He started his professional career as a medicinal chemist at Janssen Research Foundation in 1992. He then joined Tibotec in 1998, where, under his leadership, TMC114 (PrezistaTM) was selected and moved forward into clinical trials. Dr. Wigerinck also played a key role in Tibotec’s expansion into novel diseases such as Hepatitis C and advanced several compounds into Phase 1 and Phase 2 clinical trials. He brings over 15 years of research and development experience from both big pharma and biotech to Galapagos. Piet Wigerinck holds a PhD from the K.U. Leuven and is inventor on more than 25 patent applications.

Bart Filius, MBA - Chief Financial Officer

Bart Filius joined Galapagos as Chief Financial Officer in December 2014. Prior to that, Bart worked over 13 years at Sanofi, where he was CFO Sanofi Europe the last three years and was instrumental in transforming the Sanofi European organization to be well-positioned beyond the patent cliff. Earlier at Sanofi, Bart was CFO and Country Manager of Sanofi in the Netherlands. Before that, he was Vice President for Mergers & Acquisitions, during which time Bart led and completed the divestiture of various franchises. Prior to joining Sanofi, Bart was a strategy consultant at Arthur D. Little. Bart is a Dutch national and has an MBA degree from INSEAD and a bachelor’s degree in business from Nyenrode University.

Andre Hoekema, PhD - Senior Vice President Corporate Development

Dr. Hoekema joined Galapagos in March 2005 from Invitrogen Corporation, where he was Managing Director of Corporate Development Europe. He brings 20 years of biotech experience from positions at Molecular Probes Europe (Managing Director), Crucell (Director of Business Development), DSM Life Sciences and MOGEN (Research and Project Management) and Genentech, Inc (R&D). Dr. Hoekema has a PhD degree from Leiden University and is the inventor of over 20 series of patent applications, resulting in 15 patents issued in the US. Dr. Hoekema currently also serves as a member of the supervisory board of Mimetas B.V.